As part of its efforts to rally global support for India’s war against terror emanating from Pakistan and moving to isolate Islamabad internationally, the ...

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...

The Court found that Amgen violated antitrust and tort laws by creating a bundling scheme that illegally leveraged its blockbuster anti-inflammatory drugs Enbrel (etanercept) and Otezla (apremilast) ...

Regeneron sued in 2022, claiming that Amgen unfairly tied its cholesterol drug Repatha to rebates on two of its blockbuster treatments - Enbrel, used for rheumatoid arthritis, and Otezla, a psoriasis ...

The pharmaceutical company claimed Amgen bundled anti-inflammatory drugs Enbrel and Otezla to convince pharmacy benefit managers to select Repatha as the exclusive PCSK9 category product over ...

In turn, the jury has put Amgen on the hook to pay Regeneron $135.6 million in compensatory damages and another $271.2 million in punitive damages, according to a verdict form filed Thursday.

The pharmaceutical company claimed Amgen bundled anti-inflammatory drugs Enbrel and Otezla to convince pharmacy ... on this site does not imply any form of partnership, agency, or endorsement.

TOKYO -- Renesas Electronics has signed an agreement with an Indian government-affiliated scientific organization to provide semiconductor design and development software to startups and ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

and the divestiture of Otezla ® to Amgen Appointment marks a key addition as Tonix readies for the potential approval of TNX-102 SL for the management of fibromyalgia next quarter CHATHAM, N.J., May ...